Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Rhinosinusitis; Sinusitis
- Focus Therapeutic Use
- Acronyms Liberty CRSsNP; Liberty CRSsNP ORION
- Sponsors Sanofi
- 12 Feb 2024 Status changed from active, no longer recruiting to completed.
- 11 Feb 2024 This trial has been Discontinued in Poland, According to European Clinical Trials Database record.
- 26 Jul 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.